Supernus Pharmaceuticals Stock Book Value Per Share
| SUPN Stock | USD 32.15 0.17 0.53% |
Supernus Pharmaceuticals fundamentals help investors to digest information that contributes to Supernus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Supernus Stock. The fundamental analysis module provides a way to measure Supernus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Supernus Pharmaceuticals stock.
Supernus |
Supernus Pharmaceuticals Company Book Value Per Share Analysis
Supernus Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Supernus Pharmaceuticals Book Value Per Share | 18.58 X |
Most of Supernus Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Supernus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Supernus Pharmaceuticals is about 18.58 times. This is 1192.94% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The book value per share for all United States stocks is 99.04% higher than that of the company.
Supernus Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Supernus Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Supernus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Supernus Pharmaceuticals by comparing valuation metrics of similar companies.Supernus Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Supernus Fundamentals
| Return On Equity | 0.0755 | ||||
| Return On Asset | 0.029 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 55.81 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 95.00 % | ||||
| Number Of Shares Shorted | 5.72 M | ||||
| Price To Earning | 15.25 X | ||||
| Price To Book | 1.73 X | ||||
| Price To Sales | 2.71 X | ||||
| Revenue | 661.82 M | ||||
| Gross Profit | 583.91 M | ||||
| EBITDA | 178.28 M | ||||
| Net Income | 73.86 M | ||||
| Cash And Equivalents | 360.79 M | ||||
| Cash Per Share | 6.74 X | ||||
| Total Debt | 34.27 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 0.85 X | ||||
| Book Value Per Share | 18.58 X | ||||
| Cash Flow From Operations | 171.95 M | ||||
| Short Ratio | 10.08 X | ||||
| Earnings Per Share | 1.32 X | ||||
| Price To Earnings To Growth | 1.47 X | ||||
| Target Price | 38.8 | ||||
| Number Of Employees | 674 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 1.79 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | 556.43 M | ||||
| Working Capital | 393.67 M | ||||
| Current Asset | 105.95 M | ||||
| Current Liabilities | 56.93 M | ||||
| Net Asset | 1.37 B |
About Supernus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Supernus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Supernus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Supernus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Supernus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Supernus Stock
Moving against Supernus Stock
| 0.72 | OCX | OncoCyte Corp | PairCorr |
| 0.67 | GILD | Gilead Sciences | PairCorr |
| 0.56 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.45 | GOSS | Gossamer Bio | PairCorr |
| 0.42 | SNY | Sanofi ADR | PairCorr |
The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Supernus Pharmaceuticals Piotroski F Score and Supernus Pharmaceuticals Altman Z Score analysis. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.